Tania Jain

Tania Jain

Hematology Oncology
401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

Journal: Seminars in hematology
Published: July 26, 2026

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026

Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021.

Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021.

Journal: Research square
Published: May 18, 2026

Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Journal: Leukemia
Published: April 23, 2026

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Journal: Transplantation and cellular therapy
Published: April 03, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)
Published: March 07, 2026

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma
Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica
Published: February 15, 2026

GW240925 and GW250207: Astrophysical Calibration of Gravitational Wave Detectors.

GW240925 and GW250207: Astrophysical Calibration of Gravitational Wave Detectors.

Journal: Physical review letters
Published: January 27, 2026

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: January 14, 2026

Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.

Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.

Journal: JCO oncology practice
Published: December 15, 2025

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Journal: Transplantation and cellular therapy
Published: October 09, 2025
Showing 1-12 of 141

Last Updated: 09/26/2026